Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study.

Dipeptidyl Peptidase-4 (DPP-4), the target of oral antidiabetic drugs DDP-4 inhibitors, has been suggested to be involved in the pathogenesis of coronavirus infections, including COVID-19. It is unclear whether the routine use of DPP-4 inhibitors increases the severity of COVID-19 in people with type 2 diabetes (T2D). Our purpose was to investigate the association between routine use of DPP-4 inhibitors and the severity of COVID-19 infection in a large multicentric study.